D.E. Shaw & Co
NBIX icon

D.E. Shaw & Co’s Neurocrine Biosciences NBIX Stock Holding History

D.E. Shaw & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$1.23M – 3913
2018
Q3 		$1.23M Hold
10,000
– – ﹤0.01% 2547
2018
Q2 		$982K Buy
+10,000
New +$895K ﹤0.01% 2715

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co's NBIX Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Neurocrine Biosciences (NBIX) stake by 94% in Q2 2026, selling an estimated $12.4M and leaving 5,599 shares worth $944K. The position accounts for ﹤0.01% of the portfolio, ranked #3786.

D.E. Shaw & Co first reported a position in NBIX in Q2 2013 and has held it in 46 quarters since. The position peaked at $30.9M in Q4 2022. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • D.E. Shaw & Co held 5,599 shares of Neurocrine Biosciences worth $944K as of Q2 2026.
  • D.E. Shaw & Co sold 83,585 Neurocrine Biosciences shares in Q2 2026, an estimated $12.4M.
  • Neurocrine Biosciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3786 holding.
  • D.E. Shaw & Co first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 46 quarters since.
  • D.E. Shaw & Co's Neurocrine Biosciences position peaked at $30.9M in Q4 2022.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.